

# RETROPERITONEAL ROBOTIC PARTIAL NEPHRECTOMY: SYSTEMATIC REVIEW AND CUMULATIVE ANALYSIS OF COMPARATIVE OUTCOMES

Nicola Pavan<sup>1</sup>, Ithaa Derweesh<sup>2</sup>, Lance J. Hampton<sup>3</sup>, Wesley M. White<sup>4</sup>, James Porter<sup>5</sup>,  
Ben Challacombe<sup>6</sup>, Prokar Dasgupta<sup>6</sup>, Riccardo Bertolo<sup>7</sup>, Jihad Kaouk<sup>7</sup>,  
Vincenzo Mirone<sup>8</sup>, Francesco Porpiglia<sup>9</sup>, Riccardo Autorino<sup>3</sup>

<sup>1</sup>Urology Clinic, University of Trieste, Trieste, Italy; <sup>2</sup>Department of Urology, UC San Diego Health System, La Jolla, CA, USA; <sup>3</sup>Division of Urology, Virginia Commonwealth University, Richmond, VA, USA; <sup>4</sup>Department of Urology, The University of Tennessee Medical Center, Knoxville, TN, USA; <sup>5</sup>Swedish Urology Group, Seattle, WA, USA; <sup>6</sup>Urology Centre, Guy's Hospital, King's College, London, UK; <sup>7</sup>Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA; <sup>8</sup>Department of Urology, School of Medicine, University of Naples Federico II, Naples, Italy; <sup>9</sup>Department of Urology, University of Turin-San Luigi Gonzaga Hospital, Turin

## Corresponding Author

Riccardo Autorino, MD, PhD, FEBU  
Clinical Associate Professor of Urology  
Virginia Commonwealth University  
McGuire VA Medical Center  
1210 Broad block Blvd., Richmond, VA, 23249, USA  
Phone: +1 8056752169  
email: [ricautor@gmail.com](mailto:ricautor@gmail.com)

**Key words:** *comparative outcomes; kidney neoplasms; robotic partial nephrectomy; retroperitoneal approach; robotic surgery*

**Running head:** *Transperitoneal versus retroperitoneal robotic partial nephrectomy*

**Word count:** manuscript: 2240

**Figures: 2; Tables: 2**

**Supplementary Figures: 1**

## ABSTRACT

**OBJECTIVES:** To compare the outcomes of retroperitoneal versus transperitoneal approach for robot assisted partial nephrectomy (RAPN).

**MATERIALS AND METHODS:** A systematic review of the literature was performed through January 2018 using PubMed, Scopus, and Ovid databases. Article selection proceeded according to the search strategy based on PRISMA criteria. Only studies comparing retroperitoneal to transperitoneal approach for RAPN were deemed eligible for inclusion.

**RESULTS:** Seven retrospective case-control studies were identified and included in the analysis, with a total number of 1379 patient (866 for transperitoneal group; 513 for retroperitoneal group). In the retroperitoneal group, tumours were slightly larger (WMD: 0.29 cm; 95% CI: 0.04-0.54;  $p=0.02$ ), and more frequently located posterior/lateral (OR: 0.61; 95% CI: 0.41-0.90;  $p=0.01$ ). In two of the studies only posterior tumours had been included. Both operating time (WMD 20.17 min; 95% CI 6.46-33.88;  $p=0.004$ ) and estimated blood loss (WMD 54.57 mL; 95% CI 6.73-102.4;  $p=0.03$ ) were significantly lower in the retroperitoneal group. Also, length of stay was significantly shorter in the retroperitoneal group (WMD 0.46 days; CI 95% 0.15-0.76;  $p=0.003$ ). No differences were found regarding overall ( $p=0.67$ ) and major ( $p=0.82$ ) postoperative complications, warm ischemia time ( $p=0.96$ ), and positive surgical margins ( $p=0.95$ ).

**CONCLUSIONS:** Retroperitoneal RAPN can offer in select patients similar outcomes to those of the most common transperitoneal RAPN. Furthermore, it may be particularly advantageous for posterior upper pole and perihilar tumors and associated with reduction in operative time and hospital stay. Robotic surgeons should be ideally familiar with both approaches to adapt their surgical strategy to confront renal neoplasms from a position of technical advantage and ultimately optimize outcomes.

## 1. INTRODUCTION

Partial nephrectomy (PN) represents an established treatment option for small (clinical T1a) renal masses (T1a)<sup>1,2</sup>, despite the controversial findings from the only available randomized trial to date<sup>3</sup>. Moreover, recent data suggest PN to represent a viable treatment option also for select larger renal tumours as it provides equivalent cancer control and better preservation of renal function<sup>4</sup>. Over the past decade, the rapid implementation of robot-assisted surgery for PN has represented a paradigm shift in the field, facilitating a minimally invasive approach with better outcomes than standard laparoscopy<sup>5</sup>. Moreover, the adoption of robotic technology seems to favour the adoption of nephron sparing surgery<sup>6</sup>.

Both transperitoneal<sup>7,8</sup> and retroperitoneal<sup>9</sup> approaches have been described and standardised for robotic PN (RAPN). Debate is ongoing to define their role, as advantages and disadvantages of each of these two approaches are being scrutinized. Only a limited number of comparative studies have been reported, and therefore a gap exists in the literature<sup>10</sup>.

Aim of this study is to provide the most up to date systematic review and cumulative analysis of reported comparative outcomes of retroperitoneal RAPN (R-RAPN) versus transperitoneal RAPN (T-RAPN).

## 2. MATERIAL AND METHODS

### 2.1. Search strategies

A systematic revision of literature was performed up to January 2018 using different search engines (Pubmed, Ovid, Scopus) to identified studies comparing R-RAPN to T-RAPN. A review protocol was established prior to conduct the study. The PICO model was as follows: population consisted of patients with renal mass (P) who underwent RAPN with retroperitoneal approach (I) or standard transperitoneal approach (C). Outcomes of interest were perioperative outcomes (O), as detailed later. Identification and selection of the studies was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analysis criteria ([www.prisma-statement.org](http://www.prisma-statement.org)) (**Figure 1**). Separate searches were

performed using a combination of search terms *nephron sparing*, *retroperitoneal*, *retroperitoneoscopic*, *robotic partial nephrectomy*.

## 2.2. Selection criteria

Two of the authors (NP and RA) performed the article selection, which was limited to English language only and with adult patients. Only original studies comparing the outcomes of retroperitoneal and transperitoneal RAPN for renal tumors were included. Title and abstracts were first review to ascertain whether they would potentially follow the inclusion criteria. For those passing the first screening, a full text analysis was performed to confirm inclusion. Studies without primary data (letters to the editor/authors, case reports and commentaries) as well as conference abstracts were not considered. References of collected studies were manually reviewed to find additional studies of interest.

## 2.3. Assessment of study quality and publication bias

We classified each study according to the level of evidence (<http://www.cebm.net/explanation-2011-ocbm-levels-evidence/>). The quality of the studies was determined using the Newcastle-Ottawa scale (NOS) for non-randomized controlled trials ([http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)). A total score of 5 or less was considered low quality, 6–7 was considered intermediate quality, and 8–9 was considered high quality. Risk of publication bias was assessed by using funnel plots.

## 2.4. Data extraction and analysis

Data were extracted from each selected study. Baseline demographics [age, gender, BMI, pre-operative estimated glomerular filtration rate (eGFR), tumour size, RENAL nephrometry score<sup>11</sup>, side, and location), intraoperative data [(operative time (OT), estimated blood loss (EBL), warm ischemia time (WIT)], and postoperative outcomes [complications (minor and major, according to Clavien-Dindo<sup>12</sup>), hospital stay, and positive surgical margin (PSM) rate].

For continuous outcomes, the weighted mean difference (WMD) was used as a summary measure, whereas the odds ratio (OR) or risk ratio (RR) with 95% confidence

interval (CI) was calculated for binary variables. RR was preferred in cases of a high number of events to avoid overestimation. As only means and standard deviations are permitted for the computational portion of meta-analyses, a validated mathematical model was used to convert median (range) to mean (standard deviation) for studies reporting medians and ranges<sup>13</sup>. Pooled estimates were calculated using the random-effect model to account for study heterogeneity. Evaluation of potential publication bias was done by funnel plots analysis for each outcome. All statistical analyses were performed using Review manager 5 (Cochrane Collaboration, Oxford, UK). The study was prospectively registered and approved by the PROSPERO website (<http://www.crd.york.ac.uk/PROSPERO>, registration number CRD42017064102).

### 3. RESULTS

#### 3.1. Description of included studies and quality assessment

Seven studies were identified and included for the analysis<sup>14-20</sup> (**Table 1**), which were published between 2013 and 2018. None of them was a randomized clinical trial. Three studies were observational retrospective case-control studies, three of them were retrospective matched cohort studies, and one was a prospective non-randomized study. Study quality was high for all studies. Due to small number of studies, visual assessment was unlikely to be accurate, but no obvious publication bias was observed.

#### 3.2. Demographics and clinical characteristics

Among the 1379 patients included in the meta-analysis, 866 (62.8%) were T-RAPN and 513 (37.2%) R-RAPN. **Table 2** summarizes patient and tumour characteristics. There was no difference between groups in terms of gender ( $p=0.50$ ), age ( $p=0.40$ ), BMI ( $p=0.09$ ), RENAL score ( $p=0.74$ ), and tumour side ( $p=0.97$ ). In the R-RAPN group, tumors were slightly larger (WMD 0.29 cm;  $p=0.02$ ), and more frequently posterior/lateral (RR 0.61;  $p=0.01$ ). To note, in 2 studies only posterior tumors were considered<sup>16,17</sup>. The baseline eGFR was lower in R-RAPN group (WMD -3.63 mL/min;  $p<0.001$ ).

### 3.3. Surgical outcomes

Forest plots for main intraoperative outcomes are illustrated in **Figure 2**. Both OT (WMD 20.17 min; 95% CI 6.46-33.88;  $p=0.004$ ) and EBL (WMD 54.57 mL; 95% CI 6.73-102.4;  $p=0.03$ ) were significantly lower in the R-RAPN group, whereas no significant differences were found in terms of WIT (WMD -0.04 min; 95% CI -1.76-1.68;  $p=0.96$ ).

Overall complication rate was 12.8% and 13.3% for T-RAPN and R-RAPN, respectively, and no difference was found between groups (OR 1.08; 95% CI 0.77-1.52;  $p=0.67$ ). Major complication rates were 2.7% and 3.4% for T-RAPN and R-RAPN, respectively, and similarly no difference was found between groups (OR 0.94; 95%CI 0.52-1.69;  $p=0.82$ ). Positive surgical margins rates were 2.2% and 2.9% for the T-RAPN and R-RAPN, respectively (OR 0.98; 95% CI 0.47-2.06;  $p=0.95$ ). Last, the hospital stay was significantly shorter in the R-RAPN group (WMD 0.46 days; CI 95% 0.15-0.76;  $p=0.003$ ) (**Figure 3**).

## 4. DISCUSSION

Herein we present the largest cumulative analysis to date of studies comparing the retroperitoneal versus transperitoneal approach for RAPN. Overall, our findings suggest that both approaches may offer equivalent and optimal surgical quality, and short-term oncologic and functional outcomes for both anterior and posterior masses. Not surprisingly, the retroperitoneal approach is preferred for posteriorly located tumors, and it might offer an advantage in terms of shorter operative time, lower EBL, and shorter hospital stay. The clinical impact of these differences however seems to be negligible with respect to functional recovery and oncological efficacy, and it remains to be determined with respect to quality of life indices.

In the only other similar analysis, reported by Xia et al, only 4 studies were included for a total of 449 patients, and no significant difference was found in any of the only outcome of interest, except for a marginally shorter operative time for the R-RAPN group (WMD: 28.03; 95% CI 0.41-55.65;  $p=0.05$ )<sup>21</sup>. This difference has become statistically more significant in our analysis (WMD 20.17 min; 95% CI 6.46-33.88;  $p=0.004$ ), likely due to the larger sample. The shorter operative time was reported in four of the studies included in

our analysis<sup>14-16,19,20</sup>. Intuitively, Hughes-Hallet et al explained this result by considering that a retroperitoneal approach allows to access the renal hilum without colon mobilization<sup>14</sup>. In this regard, it should be acknowledged how patient selection impacts cumulative findings. Most surgeons preferring a transperitoneal approach would still use this approach for posterior tumor, and spend more time doing so. In that regard, they could consider a retroperitoneal approach. On the other hand, approaching some tumors, such as large (clinical T2+) or highly complex tumors, or lower pole tumors, using a retroperitoneal approach might be more challenging.

Another significant difference found in our analysis was the lower EBL for the R-RAPN group, which, however, despite reaching the statistical significance ( $p=0.03$ ), might not be clinically significant (about 55 ml). A reduction in EBL in the retroperitoneal group was also reported in a previous comparative study including laparoscopic and robotic PN cases reported by Gin et al<sup>22</sup>. Hughes-Hallet et al reported a significantly lower EBL in the R-RAPN group when compared to the T-RAPN group (88 vs 395 mL,  $p<0.01$ ), and the authors explained this difference by the larger use of an early unclamping technique in the T-RAPN, but also by the reduced surgical dissection needed in the retroperitoneal access<sup>14</sup>.

Regarding other relevant intraoperative outcomes, it is worth mentioning that no difference was found for the WIT between the two approaches. In all the studies, mean WIT for both groups were under the 25-30 min cut-off which has been traditionally considered as a benchmark to reach for functional preservation<sup>23,24</sup>. This might be explained by the fact that Centers and surgeons reporting these studies had become proficient with both RAPN techniques.

Our cumulative analysis confirmed an overall shorter hospital stay for the R-RAPN group of about half day (WMD 0.46 days; CI 95% 0.15-0.76;  $p=0.003$ ). According to Maurice et al., a faster recovery of bowel function represents a potential advantage of R-RAPN, which can translate into an earlier discharge, and therefore shorter hospital stay. This group reported a mean of 2.2 days in the R-RAPN group versus 2.6 days in the T-RAPN group ( $p=0.01$ )<sup>18</sup>. A significant reduction in the hospitalization time was also recorded by Hughes-Hallet et al. (4.6 days for the T-RAPN vs 2.5 days for the R-RAPN group;  $p<0.01$ )<sup>14</sup>.

Moreover, Kim et al. reported transperitoneal approach for RAPN to be a significant predictor of hospital stay greater than 1 day (OR=7.4,  $p<0.01$ ) on a multivariate analysis when controlling for age, sex, BMI, patient comorbidity, previous abdominal surgery, baseline kidney function, nephrometry score and tumour size<sup>17</sup>. More recently, Laviana et al found R-RAPN to be associated with a 76% lower probability of hospital stay at least 2 days ( $p<0.001$ )<sup>20</sup>. These authors also performed a cost analysis and found that the shorter hospital stay, and operative time were the main driving costs which resulted in an overall reduced cost for the R-RAPN group (minus 2337 USD). Of course, these findings might not be generalizable to other hospital settings. Moreover, one can argue that postoperative hospital stay is not only depending on the surgical technique, and it can be influenced by factors other than preoperative parameters. In this regard, it has been shown that outpatient transperitoneal laparoscopic nephrectomy can be safely implemented in well informed and selected patient, given appropriate hospital setup<sup>25</sup>.

In the field of laparoscopic kidney surgery, Fan et al. reported a meta-analysis including 6 studies comparing transperitoneal versus retroperitoneoscopic PN and found shorter operative time (WMD: 48.85 min;  $p<0.001$ ) and shorter length of stay (WMD 1.01 days;  $p=0.001$ ) for the retroperitoneoscopic group<sup>26</sup>. Therefore, similar differences in the case of standard laparoscopy were detected for these two parameters, and even at larger extent than for robot assisted laparoscopy. It might be speculated that the use of a robotic platform might attenuate these differences by facilitating surgeons to become proficient in both transperitoneal and retroperitoneal approach. Certainly, the adoption of robotic technology for minimally invasive PN seems to offer better outcomes<sup>27,28</sup>, likely allowing a larger adoption of nephron-sparing surgery<sup>29</sup>.

The positive margin rate for both groups/approaches in our analysis was below 3%, which is a desirable figure, in line with literature from high volume institutions for PN<sup>30,31</sup>. As the oncological significance of this surrogate oncological parameter remains to be defined, surgeons should thrive to leave “no tumor behind”<sup>30</sup>.

Some limitations of our study need to be acknowledged. The major limitation is related to the design of included studies. Despite representing a robust statistical tool,



meta-analyses certainly carry intrinsic biases, and randomized controlled trials should ideally be included. In our analysis, most of the studies were either retrospective or prospective non-randomized, however of good quality. Moreover, our cumulative analysis was necessarily limited to certain parameters that were extractable and available. For example, it was not possible to perform any functional outcome analysis<sup>32</sup>. Moreover, more robust oncological outcomes, other than the positive surgical margin rate, were also not available for analysis. To note, it was not possible to account for existing differences among institutions and surgeons in terms of surgical technique and expertise, as well as protocols of perioperative management and follow-up. Further, it would be interesting to assess how the introduction of the Xi system might facilitate a retroperitoneal approach on larger or lower pole masses, due to less clashing compared to Si system. Despite these limitations, we can provide the best available evidence in the field, and therefore our findings can be used as reference for further clinical investigation. In the future, further comparative prospective ideally randomized multi-center studies are needed to better clarify the role of one versus the other access for RAPN.

## 5. CONCLUSIONS

Notwithstanding the intrinsic limitations of this type of cumulative analysis, our findings show that R-RAPN offers similar outcomes to those of the T-RAPN in select patients. Furthermore, it may be particularly advantageous for posterior upper pole and perihilar tumors and it might translate into shorter operative time and hospital stay. While further clinical investigation is warranted to confirm these findings and ultimately provide a higher level of evidence, it is likely that T-RAPN will remain the preferred approach in the hands of many. However, robotic surgeons should be ideally familiar with both approaches to adapt their surgical strategy to confront renal neoplasms from a position of technical advantage and ultimately optimize outcomes.

## REFERENCES

1. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol.* 2015 May;67(5):913-24
2. Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. *J Urol.* 2017 Sep;198(3):520-529
3. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol.* 2011 Apr;59(4):543-52
4. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. *Eur Urol.* 2017 Apr;71(4):606-617.
5. Leow JJ, Heah NH, Chang SL, Chong YL, Png KS. Outcomes of Robotic versus Laparoscopic Partial Nephrectomy: an Updated Meta-Analysis of 4,919 Patients. *J Urol.* 2016 Nov;196(5):1371-1377
6. Patel HD, Mullins JK, Pierorazio PM, et al. Trends in renal surgery: robotic technology is associated with increased use of partial nephrectomy. *J Urol.* 2013 Apr;189(4):1229-3
7. Kaouk JH, Khalifeh A, Hillyer S, Haber GP, Stein RJ, Autorino R. Robot-assisted laparoscopic partial nephrectomy: step-by-step contemporary technique and surgical outcomes at a single high-volume institution. *Eur Urol.* 2012 Sep;62(3):553-6
8. Mottrie A, De Naeyer G, Schatteman P, Carpentier P, Sangalli M, Ficarra V. Impact of the learning curve on perioperative outcomes in patients who underwent robotic partial nephrectomy for parenchymal renal tumours. *Eur Urol.* 2010 Jul;58(1):127-32
9. Hu JC, Treat E, Filson CP, et al. Technique and outcomes of robot-assisted retroperitoneoscopic partial nephrectomy: a multicenter study. *Eur Urol.* 2014 Sep;66(3):542-9.

10. Xia L, Zhang X, Wang X, Xu T, Qin L, Zhang X, Zhong S, Shen Z. Transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: A systematic review and meta-analysis. *Int J Surg*. 2016 Jun; 30:109-15
11. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. *The Journal of urology*. 2009;182(3):844-53.
12. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey *Ann Surg*. 2004; 240(2):205-13.
13. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol*. 2005; 5:13.
14. Hughes-Hallett A, Patki P, Patel N, Barber NJ, Sullivan M, Thilagarajah R. Robot-assisted partial nephrectomy: a comparison of the transperitoneal and retroperitoneal approaches. *J Endourol*. 2013 Jul;27(7):869-74.
15. Tanaka K, Shigemura K, Furukawa J, Ishimura T, Muramaki M, Miyake H, Fujisawa M. Comparison of the transperitoneal and retroperitoneal approach in robot-assisted partial nephrectomy in an initial case series in Japan. *J Endourol*. 2013 Nov;27(11):1384-8.
16. Choo SH, Lee SY, Sung HH, Jeon HG, Jeong BC, Jeon SS, Lee HM, Choi HY, Seo SI. Transperitoneal versus retroperitoneal robotic partial nephrectomy: matched-pair comparisons by nephrometry scores. *World J Urol*. 2014 Dec;32(6):1523-9.
17. Kim EH, Larson JA, Potretzke AM, Hulsey NK, Bhayani SB, Figenschau RS. Retroperitoneal Robot-Assisted Partial Nephrectomy for Posterior Renal Masses Is Associated with Earlier Hospital Discharge: A Single-Institution Retrospective Comparison. *J Endourol*. 2015 Oct;29(10):1137-42.
18. Maurice MJ, Kaouk JH, Ramirez D, et al. Robotic Partial Nephrectomy for Posterior Tumors Through a Retroperitoneal Approach Offers Decreased Length of Stay Compared with the Transperitoneal Approach: A Propensity-Matched Analysis. *J Endourol*. 2017 Feb;31(2):158-162.
19. Stroup SP, Hamilton ZA, Marshall MT, et al. Comparison of retroperitoneal and transperitoneal robotic partial nephrectomy for Pentafecta perioperative and renal

functional outcomes. *World J Urol.* 2017 Jun 27. doi: 10.1007/s00345-017-2062-0.  
[Epub ahead of print]

20. Laviana AA, Tan HJ, Hu JC, Weizer AZ, Chang SS, Barocas DA. Retroperitoneal versus transperitoneal robotic-assisted laparoscopic partial nephrectomy: a matched-pair, bicenter analysis with cost comparison using time-driven activity-based costing. *Curr Opin Urol.* 2018 Mar;28(2):108-114.
21. Xia L, Zhang X, Wang X, Xu T, Qin L, Zhang X, et al. Transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: A systematic review and meta-analysis. *Int J Surg.* 2016; 30:109-15.
22. Gin GE, Maschino AC, Spaliviero M, Vertosick EA, Bernstein ML, Coleman JA. Comparison of perioperative outcomes of retroperitoneal and transperitoneal minimally invasive partial nephrectomy after adjusting for tumor complexity. *Urology.* 2014;84(6):1355-60.
23. Mir MC, Pavan N, Parekh DJ. Current Paradigm for Ischemia in Kidney Surgery. *J Urol.* 2016 Jun;195(6):1655-63.
24. Rod X, Peyronnet B, Seisen T, et al. Impact of ischaemia time on renal function after partial nephrectomy: a systematic review. *BJU Int.* 2016 Nov;118(5):692-705
25. Azawi NH, Christensen T, Dahl C, Lund L. Pushing the Envelope: Laparoscopic Nephrectomy as Outpatient Surgery. *Curr Urol Rep.* 2018 Jan 27;19(1):2. doi: 10.1007/s11934-018-0751-x.
26. Fan X, Xu K, Lin T, et al. Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a systematic review and meta-analysis. *BJU Int.* 2013 Apr;111(4):611-21
27. Leow JJ, Heah NH, Chang SL, Chong YL, Png KS. Outcomes of Robotic versus Laparoscopic Partial Nephrectomy: an Updated Meta-Analysis of 4,919 Patients. *J Urol.* 2016 Nov;196(5):1371-1377.
28. Khalifeh A, Autorino R, Hillyer SP, et al. Comparative outcomes and assessment of trifecta in 500 robotic and laparoscopic partial nephrectomy cases: a single surgeon experience. *J Urol.* 2013 Apr;189(4):1236-42

29. Patel HD, Mullins JK, Pierorazio PM, et al. Trends in renal surgery: robotic technology is associated with increased use of partial nephrectomy. *J Urol*. 2013 Apr;189(4):1229-35.
30. Khalifeh A, Kaouk JH, Bhayani S, et al. Positive surgical margins in robot-assisted partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor behind). *J Urol*. 2013 Nov;190(5):1674-9.
31. Minervini A, Campi R, Sessa F, et al. Positive surgical margins and local recurrence after simple enucleation and standard partial nephrectomy for malignant renal tumors: systematic review of the literature and meta-analysis of prevalence. *Minerva Urol Nefrol*. 2017 Dec;69(6):523-538. doi: 10.23736/S0393-2249.17.02864-8
32. Bertolo RG, Zargar H, Autorino R, et al. Estimated glomerular filtration rate, renal scan and volumetric assessment of the kidney before and after partial nephrectomy: a review of the current literature. *Minerva Urol Nefrol*. 2017 Dec;69(6):539-547. doi:10.23736/S0393-2249.17.02865-X

## LIST OF ABBREVIATIONS

Robotic partial nephrectomy = RAPN

Retroperitoneal robotic partial nephrectomy = R-RAPN

Transperitoneal robotic partial nephrectomy = T-RAPN

Body mass index = BMI

Estimated glomerular filtration rate = eGFR

Operative time = OT

Estimated blood loss = EBL

Warm ischemia time = WIT

Positive surgical margin = PSM

Weighted mean difference = WMD

Odds ratio = OR

Risk ratio = RR

Confidence interval = CI

**Table 1. Overview of studies quality and characteristics**

References	Study design	Study setting	Study origin	N cases (RRPN/TRPN)	Study quality <sup>a</sup>
Hughes-Hallett <sup>14</sup>	Retrospective	Multi-center	UK	44/59	7
Kim <sup>17</sup>		Single-center	USA	116/97	7
Stroup <sup>19</sup>		Two-center	USA	141/263	7
Choo <sup>16</sup>	Retrospective Matched pair	Single-center	Korea	50/57	8
Maurice <sup>18</sup>		Multi-center	USA	74/296	8
Laviana <sup>20</sup>		Bi-center	USA	78/78	8
Tanaka <sup>15</sup>	Prospective non-randomized	Single-center	Japan	10/16	8

Level of evidence for all studies: IIIb (according to Oxford Centre for Evidence-based Medicine)

<sup>a</sup>According to Newcastle Ottawa scale; RRPN=Retroperitoneal group; TRPN=Transperitoneal group

**Table 2. Patients and tumour characteristics (Transperitoneal versus Retroperitoneal approach)**

Variable	No of studies where data available	Mean Difference/Odds ratio/Risk ratio	95% CI	p value
Male Gender, n	6	0.98	0.89, 1.07	0.60
Age, years	7	-0.77	-2.55, 1.01	0.40
BMI, m <sup>2</sup> /kg	4	-0.39	-0.84, 0.06	0.09
Baseline eGFR, ml/min	3	-3.63	-5.59, -1.67	0.0003
Tumor size, cm	6	0.29	0.04, 0.54	0.02
RENAL score, n	6	0.03	-0.20, 0.26	0.82
Posterior/lateral location*, n	7	0.61	0.41, 0.90	0.01
Right side, n	7	1.01	0.91, 1.12	0.88

\*In two studies (Kim 2015 and Maurice 2017) ONLY posterior tumors considered



FIGURE LEGENDS





Figure 1. PRISMA flow for study selection and inclusion.

**Operative time**

Study or Subgroup	Transperitoneal			Retroperitoneal			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
Tanaka J Endo 2013	239	63	16	193	40.6	10	7.2%	46.00 [6.17, 85.83]	2013
Hughes-Hallet J Endo 2013	205	66.4	59	155	42.4	44	12.9%	50.00 [28.93, 71.07]	2013
Choo WJU 2014	149	22.4	57	120	14.9	50	17.6%	29.00 [21.87, 36.13]	2014
Kim J Endo 2015	149	44	97	152	44	116	16.2%	-3.00 [-14.87, 8.87]	2015
Stroup WJU 2017	231.7	70.4	263	217.2	61.9	141	15.8%	14.50 [1.20, 27.80]	2017
Maurice J Endo 2017	176	58	523	176	59	87	15.7%	0.00 [-13.36, 13.36]	2017
Laviana Curr Opin Urol 2018	191.1	60.3	78	167	44.3	78	14.5%	24.10 [7.49, 40.71]	2018
<b>Total (95% CI)</b>			<b>1093</b>			<b>526</b>	<b>100.0%</b>	<b>20.17 [6.46, 33.88]</b>	


Heterogeneity: Tau<sup>2</sup> = 264.42; Chi<sup>2</sup> = 39.40, df = 6 (P < 0.00001); I<sup>2</sup> = 85%  
 Test for overall effect: Z = 2.88 (P = 0.004)




**EBL**

Study or Subgroup	Transperitoneal			Retroperitoneal			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
Hughes-Hallet J Endo 2013	280	83.7	59	89	40.4	44	15.4%	191.00 [166.53, 215.47]	2013
Tanaka J Endo 2013	33	41.1	16	13.5	7.5	10	15.6%	19.50 [-1.17, 40.17]	2013
Choo WJU 2014	162	43.4	57	121	40.1	50	15.8%	41.00 [25.17, 56.83]	2014
Kim J Endo 2015	75	28.8	97	100	28.9	116	16.0%	-25.00 [-32.78, -17.22]	2015
Maurice J Endo 2017	190	239	523	150	62	87	15.4%	40.00 [15.72, 64.28]	2017
Stroup WJU 2017	168.7	64.9	263	120	43.3	141	15.9%	48.70 [38.09, 59.31]	2017
Laviana Curr Opin Urol 2018	299	383.9	78	203.4	575.9	78	6.0%	95.60 [-58.00, 249.20]	2018
<b>Total (95% CI)</b>			<b>1093</b>			<b>526</b>	<b>100.0%</b>	<b>54.57 [6.73, 102.40]</b>	

Heterogeneity: Tau<sup>2</sup> = 3716.29; Chi<sup>2</sup> = 353.85, df = 6 (P < 0.00001); I<sup>2</sup> = 98%  
 Test for overall effect: Z = 2.24 (P = 0.03)



**Figure 2.** Forest plots for operative time and EBL (estimated blood loss).



**Figure 3.** Forest plots for hospital stay.